A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.

<h4>Introduction</h4> <p>There is an urgent need for a new and effective tuberculosis vaccine because BCG does not sufficiently prevent pulmonary disease. IMX313 is a novel carrier protein designed to improve cellular and humoral immunity. MVA85A-IMX313 is a novel vaccine candidate...

Full description

Bibliographic Details
Main Authors:	Minhinnick, A, Satti, I, Harris, S, Wilkie, M, Sheehan, S, Stockdale, L, Lopez-Ramon, R, Poulton, I, Lawrie, A, Vermaak, S, Le Vert, A, Del Campo, J, Hill, F, Moss, P, McShane, H, Manjaly Thomas, Z
Format:	Journal article
Language:	English
Published:	Elsevier 2016

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.

Similar Items